This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| A. Classification codes | ICD-10 C34 (C34.0 main bronchus, C34.1 upper lobe, C34.2 middle lobe, C34.3 lower lobe, C34.8 overlapping lesion, C34.9 unspecified) |
| B. Synonyms | Lung cancer, bronchial cancer, malignant tumor of the lung, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), adenocarcinoma, squamous cell carcinoma, large cell carcinoma |
| C. Adult onset | Very high — occurs mainly in people in their 50s or older; onset before age 40 accounts for less than 2% of all cases |
| Special Copayment Reduction | V193 · 5 years from the cancer patient registration date · 5% copayment |
| 1. History | Epidemiological establishment of the link between smoking and lung cancer (Doll & Hill, 1950); 20th-century lung cancer epidemic; listed as the leading cause of cancer death in Korea |
| 2. Causes | Smoking (most important), radon, asbestos, air pollution, occupational carcinogen exposure, secondhand smoke |
| 3. Genetics | EGFR (32–41% in Asians), KRAS, ALK, ROS1, RET, MET, BRAF, NTRK; TP53/RB1 (SCLC) |
| 4. Epidemiology | Leading cause of cancer death in Korea; about 30,000 new diagnoses per year; high incidence in male smokers and the elderly |
| 5. Pathophysiology | Smoking carcinogens → DNA damage to the bronchial mucosa → sequential gene mutations → carcinoma in situ → invasive cancer |
| 6. Symptoms | Cough, hemoptysis, dyspnea, chest pain, hoarseness, weight loss, loss of appetite |
| 7. Signs | Decreased breath sounds, pleural effusion, SVC syndrome, Horner syndrome, signs of Pancoast tumor, obstructive pneumonia |
| 8. Screening | Low-dose chest CT (LDCT); national cancer screening for smokers aged 54–74 with 30 or more pack-years; every 2 years |
| 9. Diagnosis | CT/PET-CT, bronchoscopy, EBUS, VATS, liquid biopsy; EGFR/ALK/ROS1/PD-L1/TMB testing; TNM staging |
| 10. Treatment | EGFR TKI (osimertinib), ALK inhibitor (alectinib), immunotherapy (pembrolizumab, nivolumab), surgery, SBRT |
| 11. Prognosis | 5-year survival rate: stage I 70–90%, stage II 40–60%, stage III 15–35%, stage IV 5–10%; dramatic improvement with targeted therapy |
| 12. Prevention | Smoking cessation, radon reduction, asbestos regulation, reduction of air pollution, enrollment in national lung cancer screening, management of occupational carcinogens |
| 13. References | NCCN Guidelines, ASCO/ESMO, Korean Association for Lung Cancer, National Cancer Center, key papers in PMC/PubMed |
Lung cancer is a disease of modern civilization that increased sharply in the 20th century with the popularization of cigarettes. Until the early 1900s, lung cancer was considered a very rare disease, but its incidence soared as cigarette consumption exploded through the two World Wars. The historic study published by Richard Doll and Austin Bradford Hill in the British Medical Journal (BMJ) in 1950 was the first to demonstrate epidemiologically a strong causal relationship between smoking and lung cancer, and it became a milestone in cancer epidemiology.
The 1964 report of the US Surgeon General on smoking and health officially established smoking as the main cause of lung cancer. Subsequently, as anti-smoking campaigns gained momentum in developed countries from the 1980s, incidence began to decline in some countries. However, in Asia, including Korea, lung cancer still holds its place as the leading cause of cancer death, and the increase in lung cancer in nonsmoking women, especially EGFR-mutant adenocarcinoma, has emerged as a new clinical challenge.
In the history of treatment as well, surgical resection was the only treatment in the mid-20th century, but treatment options expanded with the introduction of cisplatin-based combination chemotherapy in the 1970s–1980s. The discovery of EGFR mutations and the advent of gefitinib in the early 2000s opened the era of targeted therapy, and the discovery of ALK rearrangement and development of crizotinib in the 2010s demonstrated the realization of precision medicine. The clinical introduction of immune checkpoint inhibitors (PD-1/PD-L1 inhibitors) since 2016 completely changed the paradigm of lung cancer treatment.
In Korea, lung cancer began to be listed as the leading cause of death from malignant tumors in the 1980s, and with the founding of the Korean Association for Lung Cancer in 1995, lung cancer care in Korea was standardized. Since 2019, low-dose CT screening for lung cancer has been included in the National Cancer Screening Program, establishing a system for early detection.
The most important risk factor for lung cancer is smoking. Smokers have a 15–30 times higher risk of lung cancer than nonsmokers, and about 85% of all lung cancers are directly related to smoking. Tobacco smoke contains more than 70 carcinogens, of which polycyclic aromatic hydrocarbons (PAHs), nitrosamines, benzene, and others are known as major lung carcinogens. The risk increases proportionally with greater smoking amount, longer smoking duration, and younger age at starting.
Radon is the second most important cause of lung cancer after smoking and is a radioactive gas that occurs naturally from soil and rock. Long-term living in an environment with high indoor radon concentrations significantly raises the risk of lung cancer, and the US Environmental Protection Agency (EPA) estimates that about 21,000 lung cancer deaths per year are attributable to radon. Asbestos is another important occupational carcinogen, and combined exposure with smoking produces a synergistic effect that dramatically increases the risk.
Outdoor air pollution, especially fine particulate matter (PM2.5) and nitrogen oxides (NOx), has also been confirmed to increase lung cancer risk, and the World Health Organization (WHO) classified air pollution as a Group 1 carcinogen in 2013. Other occupational carcinogens include arsenic, chromium, nickel, cadmium, and petroleum breakdown products, and the risk of lung cancer is high among workers exposed to them in mining, smelting, and construction. Secondhand smoke is also known to increase the lung cancer risk of nonsmokers by about 20–30%.
In lung cancer in nonsmoking women, genetic susceptibility, indoor smoke generated during cooking, hormonal factors, and others appear to act in combination. This is supported by the high proportion of nonsmoking women among Korean patients with non-small cell lung cancer and the high rate of EGFR mutations in them.
The molecular biological understanding of lung cancer has advanced dramatically over the past 20 years and forms the foundation of modern targeted therapy. Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) show different genomic profiles.
EGFR (Epidermal Growth Factor Receptor) mutations are found in about 17% of NSCLC worldwide but are markedly higher, at 32–41%, in Asian patients. Exon 19 deletions and the exon 21 L858R point mutation are typical sensitizing mutations, and the third-generation EGFR TKI osimertinib has been established as the first-line standard treatment. KRAS mutations occur mainly in smoking-related adenocarcinoma (25–30%), and the G12C mutation in particular is the target of small-molecule inhibitors (sotorasib, adagrasib). ALK rearrangements account for 3–5% of all NSCLC and occur mainly in adenocarcinomas of young nonsmoking patients. Second- and third-generation ALK inhibitors such as alectinib and brigatinib show excellent clinical outcomes.
Targeted agents have also been developed for ROS1 rearrangements (1–2%), RET rearrangements (1–2%), MET amplification and exon 14 skipping (3–4%), BRAF V600E (1–3%), and NTRK fusions (less than 1%). HER2 (ERBB2) mutations are found in about 2–4%, and trastuzumab deruxtecan has recently been approved.
SCLC is characterized by nearly universal (more than 90%) biallelic inactivation of TP53 and RB1. SCLC shows a high tumor mutational burden (TMB), but the response rate to immunotherapy alone is low. Recently, atezolizumab or durvalumab combined with platinum-etoposide has been approved as first-line treatment for extensive-stage SCLC.
The PD-L1 expression level (TPS ≥50%) is the selection criterion for first-line pembrolizumab monotherapy, and TMB-H (≥10 mut/Mb) is also used as a predictor of response to immunotherapy. The Korean Cardiopulmonary Pathology Study Group recommends first-line testing for EGFR, ALK, ROS1, and BRAF, and recommends including NTRK, MET, RET, HER2, and KRAS when results are negative or when broad panel testing is performed.
Worldwide, about 2.2 million people are newly diagnosed with lung cancer each year and about 1.8 million die of it. This accounts for about 18% of all cancer-related deaths, making it the leading cause of cancer death worldwide. By histologic type, adenocarcinoma accounts for about 40%, squamous cell carcinoma for about 25–30%, large cell carcinoma for about 10%, and small cell lung cancer (SCLC) for about 15–20%.
In Korea, lung cancer is the undisputed leading cause of cancer death; as of 2022, about 30,000 people are newly diagnosed annually and about 18,000 die of lung cancer. Incidence is higher in men than in women, but the proportion of lung cancer in female nonsmokers is increasing. The high EGFR mutation rate in nonsmoking adenocarcinoma among Korean NSCLC patients is an important epidemiological feature distinguishing Korea from Western countries.
Regarding stage distribution at diagnosis, according to the Korean Lung Cancer Registry (2014 data), stage I accounts for about 29.8%, stage II about 8.4%, stage III about 18.1%, and stage IV about 43.3%, so a considerable proportion is found at an advanced stage. The median age at onset is around 68, so it occurs mainly in the elderly, and lung cancer before age 40 is rare, at less than 2% of the total.
Worldwide, incidence is declining in high-income countries due to the effect of anti-smoking campaigns, but it is still increasing in many low- and middle-income countries. In Korea, despite declining smoking rates, the number of cases itself shows a gradual increase due to population aging and the increase in lung cancer among female nonsmokers.
Lung cancer develops through multistep carcinogenesis. Carcinogens in tobacco smoke directly damage the DNA of bronchial epithelial cells, leading to the accumulation of a series of gene mutations. It is understood that normal mucosa initially passes through the stages of hyperplasia → metaplasia → dysplasia → carcinoma in situ → invasive cancer.
At the molecular level, inactivation of the tumor suppressor genes TP53 and RB1 and activation of proto-oncogenes such as KRAS, EGFR, and ALK play key roles. EGFR mutations cause sustained phosphorylation of the receptor, keeping the RAS-MAPK and PI3K-AKT-mTOR pathways constantly active, which leads to promotion of cell proliferation, inhibition of apoptosis, and induction of angiogenesis.
In ALK rearrangement, the EML4-ALK fusion gene is formed and constitutive activation of ALK occurs, which appears mainly in young nonsmoking patients with adenocarcinoma. In small cell lung cancer, biallelic inactivation of TP53 and RB1 is central, causing complete breakdown of cell cycle regulation and neuroendocrine differentiation. In addition, reactivation of telomerase, defects in DNA damage repair mechanisms, and acquisition of immune evasion mechanisms contribute to lung cancer progression.
For adenocarcinoma in nonsmoking women, in addition to EGFR mutations, the possibility has been raised that environmental factors, hormone receptor pathways, and specific human microbiomes are involved in carcinogenesis, and this is an area of active research. In the tumor microenvironment (TME), PD-L1 expression and the distribution of tumor-infiltrating lymphocytes (TILs) are important factors determining responsiveness to immunotherapy.
Lung cancer is called the 'silent cancer' because it has no specific symptoms in the early stage. By the time symptoms appear, it has often already advanced considerably, which is the main reason early diagnosis of lung cancer is difficult.
With brain metastasis, headache, nausea, and neurological abnormalities may appear; with bone metastasis, pain or pathologic fracture at the affected site may occur. Liver metastasis may cause right upper quadrant discomfort, and adrenal metastasis may cause pain. In small cell lung cancer, paraneoplastic syndromes such as Cushing syndrome due to ectopic ACTH secretion and hyponatremia due to SIADH may occur.
Signs on physical examination vary according to the location and size of the tumor and the presence of metastasis.
When a tumor located in the lung apex invades structures of the thoracic inlet, Pancoast syndrome may occur: it is characterized by pain in the shoulder and inner arm, Horner syndrome (miosis, ptosis, anhidrosis), and upper limb weakness.
When the tumor compresses or invades the superior vena cava (SVC), swelling of the face, neck, and upper limbs, headache, jugular venous distension, and flushing of the head and neck occur. It is particularly common in SCLC and right lung tumors and is an oncologic emergency requiring immediate treatment.
Peripheral lymphadenopathy (especially supraclavicular lymph nodes), hepatomegaly, focal neurological deficits due to brain metastasis, tenderness due to bone metastasis, cutaneous metastatic nodules, and so on may be observed. Hypertrophic pulmonary osteoarthropathy is a paraneoplastic syndrome characterized by clubbing fingers. Elevated serum alkaline phosphatase (ALP) may suggest bone or liver metastasis.
The core of lung cancer screening is low-dose chest CT (Low-Dose Computed Tomography, LDCT). In the US National Lung Screening Trial (NLST) in 2011, low-dose CT screening was confirmed to lower lung cancer mortality by about 20% and all-cause mortality by about 7% compared with chest X-ray in high-risk groups.
Lung cancer screening, included in the National Cancer Screening Program since July 2019, targets high-risk individuals who meet the following conditions:
Low-dose CT uses 1/6–1/8 the radiation dose of standard chest CT while still detecting tiny lung nodules of 5mm or less, making it effective for early detection. If a lung nodule is found on screening, follow-up observation or additional tests (PET-CT, bronchoscopy, percutaneous lung biopsy, etc.) are performed depending on size, characteristics, and growth rate. The Lung-RADS classification system is used to classify the risk of nodules into categories 1–4 and provide management guidance.
Chest X-ray, performed in general health checkups, has not been proven useful as a lung cancer screening test and is not recommended for screening high-risk groups. Sputum cytology alone also has a low level of recommendation. A limitation noted for low-dose CT screening is that its high false positive rate can lead to unnecessary additional testing and patient anxiety, so expert interpretation and a counseling system to minimize this are needed.
Chest CT is the basic test for diagnosing lung cancer and evaluates tumor size, location, lymph node involvement, and pleural and vascular invasion. PET-CT is essential for evaluating distant metastasis, determining malignancy from radioactive glucose (FDG) uptake, and is used for systemic staging. Brain MRI is more sensitive than CT for evaluating brain metastasis and is performed as standard in patients with stage III–IV disease.
Bronchoscopy allows direct tissue sampling in central lung cancer, and washing cytology can also be performed. Endobronchial ultrasound (EBUS) is used for staging by performing fine-needle aspiration cytology (FNA) of mediastinal lymph nodes under real-time ultrasound guidance. Video-assisted thoracoscopic surgery (VATS) is a method that allows tissue acquisition and surgical treatment at the same time for pleural disease or peripheral lesions. Percutaneous CT-guided lung biopsy is a noninvasive method of accessing peripheral lesions.
The molecular biological tests that must be performed after tissue diagnosis are as follows:
| Test item | Test method | Clinical significance |
|---|---|---|
| EGFR mutation | PCR, NGS | Determines indication for EGFR TKI |
| ALK rearrangement | FISH, IHC, NGS | Determines indication for ALK inhibitors |
| ROS1 rearrangement | FISH, IHC, NGS | Indication for crizotinib and others |
| KRAS G12C | NGS, PCR | Indication for sotorasib |
| BRAF V600E | NGS | Dabrafenib+trametinib |
| MET exon 14 skipping | NGS | Indication for capmatinib |
| RET rearrangement | NGS | Pralsetinib, selpercatinib |
| PD-L1 expression (TPS) | IHC (22C3, 28-8) | Selection of immunotherapy |
| TMB | NGS | Prediction of immunotherapy response |
Liquid biopsy using circulating tumor DNA (ctDNA) in the blood is used, when tissue biopsy is difficult, to detect the EGFR T790M resistance mutation, monitor treatment response, and detect recurrence early. Research to standardize it and improve sensitivity is ongoing.
The AJCC/UICC 8th edition TNM staging system is used, classifying disease into stages I–IV. For SCLC, a dichotomous system dividing it into limited stage and extensive stage is also used.
In stage I–II and some stage III NSCLC, complete resection is the first-line treatment. Lobectomy is standard, and segmentectomy or wedge resection is considered in patients with limited lung function. Recently, video-assisted thoracoscopic surgery (VATS) and robot-assisted surgery have been widely used as minimally invasive methods. Osimertinib (with EGFR mutation), atezolizumab (with PD-L1 of 1% or more), and others have been approved as postoperative adjuvant therapy for resectable NSCLC.
Stereotactic body radiation therapy (SBRT/SABR) shows local control rates comparable to surgical resection in inoperable early lesions and is gradually becoming established as first-line treatment for early lesions. In unresectable stage III NSCLC, maintenance therapy with durvalumab is given after concurrent chemoradiotherapy (PACIFIC trial). The combination of SBRT and immunotherapy is currently being actively studied.
| Target | First-line agent | Notes |
|---|---|---|
| EGFR mutation | Osimertinib | Superior PFS compared with first-generation (gefitinib/erlotinib) and second-generation (afatinib) agents |
| ALK rearrangement | Alectinib | Excellent efficacy against brain metastasis; brigatinib and lorlatinib are also used |
| ROS1 rearrangement | Crizotinib, entrectinib | Crizotinib approved for first line |
| BRAF V600E | Dabrafenib+trametinib | Dual BRAF+MEK inhibition |
| MET exon 14 | Capmatinib, tepotinib | Selective MET inhibitors |
| KRAS G12C | Sotorasib, adagrasib | First KRAS-targeted therapy |
In metastatic NSCLC with PD-L1 TPS ≥50% and no EGFR/ALK alterations, pembrolizumab monotherapy is the first-line standard treatment. Regardless of PD-L1 TPS, nivolumab+ipilimumab combination or combination with chemotherapy is used. In SCLC, atezolizumab or durvalumab is combined with first-line chemotherapy.
Platinum-based doublet therapy (cisplatin or carboplatin + pemetrexed/paclitaxel/docetaxel) is standard. Pemetrexed-based regimens are preferred for adenocarcinoma, and gemcitabine-based regimens for squamous cell carcinoma.
The prognosis of lung cancer varies greatly with stage and molecular subtype at diagnosis. Overall, the 5-year survival rate is about 15–20%, which is low compared with other major cancers.
| Stage | 5-year survival rate (NSCLC) | Notes |
|---|---|---|
| Stage IA | 75~90% | With complete surgical resection |
| Stage IB | 60~73% | Surgery + adjuvant therapy |
| Stage IIA | 50~65% | Surgery + adjuvant chemotherapy |
| Stage IIB | 40~55% | Surgery + adjuvant therapy |
| Stage IIIA | 20~40% | Durvalumab after concurrent chemoradiotherapy |
| Stage IIIB/C | 10~25% | Concurrent chemoradiotherapy |
| Stage IV | 5–10% (traditional); meaningfully improved with targeted therapy | 5-year survival rate about 35–40% with EGFR TKI treatment |
In EGFR mutation-positive patients, adjuvant osimertinib significantly improved the 5-year survival rate in stage II–IIIA to 85%, compared with 73% in the placebo group (ADAURA trial). In patients with ALK rearrangement, lorlatinib treatment achieved a 4-year progression-free survival rate of 78%. The prognosis of SCLC remains poor, with a median survival of 10–13 months for extensive stage, but slight improvement is being achieved with combination immunotherapy.
The most powerful method of preventing lung cancer is smoking cessation. Smoking is the most important risk factor, and 10 years after quitting, lung cancer risk decreases to close to the level of nonsmokers. The government and the medical community should actively support smoking cessation counseling, nicotine replacement therapy, and prescription of smoking cessation aids such as varenicline and bupropion.
For radon reduction, it is important to measure radon concentrations in the home and, when necessary, take reduction measures such as improving ventilation and sealing the building. According to the standards of Korea's Ministry of Environment, the recommended indoor radon level is 200 Bq/m³. Regulation of asbestos exposure in the workplace is essential to prevent asbestos-related lung cancer and mesothelioma, and Korea has completely banned the use of asbestos since 2009.
For air pollution management, policies to reduce fine dust, regulation of old vehicles, and the transition to clean energy contribute to reducing lung cancer incidence in the long term. Because enrollment in national lung cancer screening among high-risk groups contributes to improved survival through early detection, smokers aged 54–74 with 30 or more pack-years should be guided to actively undergo low-dose CT screening. In terms of diet, intake of fresh vegetables and fruits and antioxidants may help, but caution is needed because beta-carotene supplements have been reported to actually increase lung cancer risk in smokers.